Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by EbbFlow88on Aug 11, 2023 8:41am
128 Views
Post# 35583430

RE:RE:Updated Outlook

RE:RE:Updated OutlookThanks for your input Gudisgood!

I think it helps to zoom out and look at the last 5-7 years in terms of the BD team. Prior to the GBT deal, everyone was complaining that Goodman was doing nothing with the cash and that there was nothing to find. Then in short order between 2019-21, they put close to 800M to work through GBT, Exelon and share buybacks. 

The lack of information or follow up to those valuation questions are getting tiresome but I'm not that concerned. Another deal like Exelon where you are putting 100-200M to work fixes that issue overnight. Waiting another 6-18 months for a deal like that is frustrating for all, but in the big picture won't change that much IMO.

Even a midsize deal in the ~50M range will have a decent impact and keep the cash and equivalents in a safe zone and help to diversify the portfolio but I'll defer to the management team for that as that's over my head.

I think it's mainly a timing thing regarding cash flows. I mentioned the Gilead transfer impacted that by 6M but the main factor is inventory purchases, so that will be important to keep an eye on. 


<< Previous
Bullboard Posts
Next >>